CA-VEEVA-SYSTEMS-INC.
14.5.2019 13:20:10 CEST | Business Wire | Press release
Veeva Systems (NYSE:VEEV) today introduced Veeva Andi , a new artificial intelligence (AI) application that embeds tailored insights and suggestions right in Veeva CRM for intelligent customer engagement.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190514005506/en/
Veeva Andi is part of the Veeva CRM Suite , making it easy to adopt, deploy, and scale AI across the industry’s most used CRM platform. With the unique ability to control and manage their AI solution, life sciences companies have the power to deliver the right message in the right channel at the right time for an improved customer experience.
“Veeva is empowering the life sciences industry to fully leverage AI and provide the best customer experiences,” said Peter Gassner, founder and CEO of Veeva. “Veeva Andi gives Veeva customers an open and easy-to-use AI application that provides full control to deliver intelligence and insights with greater speed and agility.”
Veeva Andi discovers relevant customer insights and proactively suggests the next best action for improved field efficiency and effectiveness. Veeva Andi gets smarter with every action, learning from a range of data, including rep feedback and customer response. When used with Customer Journeys—a new capability in Veeva CRM to better target and manage customers through stages of an adoption lifecycle—companies can drive the best actions at the right customer stage.
Veeva Andi also provides control to easily manage rules based on activities, journey stage, third party data, and HCP traits and preferences. Simulate outcomes to forecast the potential impact of insights and suggestions, then quickly deliver them to field teams in Veeva CRM to drive the right personalized customer experience.
In addition to Veeva Andi, Veeva announced new AI capabilities in Veeva CRM and Veeva Vault PromoMats . Veeva CRM Approved Notes leverages AI to help field reps build better customer relationships and remain compliant with every interaction. The new capability makes it easy for field reps to capture free text notes in Veeva CRM and use the power of AI to detect potential compliance risks. Read today’s Veeva CRM press release to learn more.
Veeva Vault Auto Claims Linking is a new capability in Veeva Vault PromoMats that will help improve speed and compliance of content development. Vault Auto Claims Linking uses AI to suggests links from claims to related references, reducing the administrative burden and risk of managing claims across countries, channels, and assets. Read the Veeva Commercial Cloud press release for more information.
Veeva Andi is available today in North America and in other regions beginning in 2020. For more information, visit veeva.com/Andi .
Registrations for Veeva Commercial & Medical Summit Europe are now open. Join us in Barcelona from 3-5 December 2019, where more than 1,200 life sciences professionals will gather to hear the latest news and market trends in the industry, experience innovative technology, and network and share best practices.
Additional Information
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow
@veeva_eu on Twitter: twitter.com/veeva_eu
Like
Veeva on Facebook: facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is the leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 700 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com .
Forward-looking Statements
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-K for the period ended January 31, 2019. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov . Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190514005506/en/
Contact:
Roger Villareal Veeva Systems 925-264-8885 roger.villareal@veeva.com
Kiran May Veeva Systems +44-796-643-2912 kiran.may@veeva.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Angel Aligner Unveils Six Innovations for 202711.11.2026 17:23:00 CET | Press release
Angel Elevates the Orthodontic Specialty by Focusing on Complex-Case Solutions Angelalign Technology Inc. (6699.HK) (“Angel”), a global clear aligner leader, has unveiled six new clinical innovations, including SuperElastic (MC-SE)* aligner material, a Deepbite Solution for significantly expanded indications, and the Adapt-MATMsystem for next generation growth guidance for young patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261110338654/en/ Unveiling Angel's 2027 Innovations. Orthodontists and opinion leaders have long remarked about Angel’s clinical excellence. Orthodontics educator and thought leader Dr. David Sarver said: “In over 4 decades, I’ve never had a parent say I’d be happy if you ensure that my child’s treatment results are average.” Angel is committed to elevating the orthodontic specialty well above the average, especially as more competition and harder referral cases demand outstanding results. Bind
Abu Dhabi Future Health Summit Concludes with Research Partnerships and New Programmes to Advance Prevention and Health Innovation11.11.2026 15:58:00 CET | Press release
Partnerships span drug discovery, clinical research, preventive and reproductive health Launch of an AI Clinician Framework and a Trusted Research Environment for health and genomic data Four whitepapers address genomics, therapeutics, fertility and wearable technologies New programmes support health innovators and entrepreneurs More than 17,300 visitors from 85 countries, with 130 speakers across 45 sessions Held under the patronage of His Highness Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of the Abu Dhabi Executive Council, Abu Dhabi Future Health Summit 2026 concluded with agreements and initiatives spanning drug discovery, clinical research, preventive and reproductive health, alongside research and entrepreneurship programmes that will sustain collaboration beyond the Summit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111545964/en/ The Summit is the annual flagship gath
De' Longhi Group: Record Results for the Quarter, With Revenue Growing by 7.7% and Net Profit Pertaining to the Group Progressing Significantly by 19%11.11.2026 15:58:00 CET | Press release
The Board of Directors of De' Longhi S.p.A. approved the consolidated results1 for the nine months of 2026. In the nine months the Group achieved: revenues for € 2,621.3 million, up by 6.5% with respect to 2025 (+7.7% at constant currency); an adjusted2 Ebitda of € 455.2 million, equal to 17.4% on revenues (vs. 15.8% with respect to last year); a net income pertaining to the Group equal to € 225.8 million (+20.4% with respect to last year); a positive net financial position equal to € 606.0 million. CEO Fabio de' Longhi commented: “The Group delivered its thirteenth consecutive quarter of organic revenue growth, underscoring our proven ability to capitalize on industry opportunities and respond promptly to market evolution, while ensuring consistent performance across both divisions. The professional business recorded a strong acceleration, spanning all geographies and brands, with revenues growth exceeding 35% for both the quarter and the nine-month period, this against an already par
Starr Chile Assigned A Rating from AM Best11.11.2026 14:30:00 CET | Press release
Starr, a global insurance and investment organization, today announced that the global credit rating agency AM Best has assigned Starr International Seguros Generales S.A. (Starr Chile) a Financial Strength Rating of A (Excellent) and a Long-Term Issuer Credit Rating of a+ (Excellent). The outlook for both credit ratings is positive. The rating reflects Starr’s strong balance sheet and Starr Chile’s successful implementation of Starr’s business model. AM Best also cited Starr’s operating performance, a favorable business profile and enterprise risk management as key factors supporting the positive rating. “This strong rating is another important endorsement of Starr’s business model as we continue to build our presence in Latin America,” said Jeff Greenberg, chairman and co-CEO of Starr. “It reflects the financial strength, underwriting discipline and experienced teams that underpin our business around the world, reinforcing the confidence brokers and clients can place in Starr.” Starr
Epinal, Inc. Emerges from Stealth with First-of-Its-Kind Breakthrough Semiconductor Electrochemical Biosensor (SEB) for Detection of Narcotics and Disease Biomarkers in Human Breath in Minutes11.11.2026 14:22:00 CET | Press release
Southern California-Based Company has developed a disruptive biosensor for integration into next-generation screening and diagnostic devices Epinal, Inc., after over six years of under-the-radar development, has officially emerged from stealth mode, introducing a breakthrough Semiconductor Electrochemical Biosensor (SEB) designed to detect narcotics and disease biomarkers directly from human breath in minutes. By combining advanced semiconductors, electrochemical sensing, tailored protein engineering, and artificial intelligence, Epinal has addressed the historical sensitivity, selectivity, scaling, stability, and signal-to-noise limitations that have long bottlenecked biosensors. Epinal’s Semiconductor Electrochemical Biosensor (SEB) will be integrated into the next generation of low cost, disposable, single-use breathalyzer cartridges where the integrity of test results is of utmost importance. In the case of narcotic detection, a rapid, non-invasive, and objective result changes an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom